A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults
← catalyst calendarNCT07612813 · readout in 390 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Prevention
Enrollment
18estimated
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-29 | actual | When the study began enrolling |
| Primary completion | 2027-09-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-13 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Staphylococcus Aureus Bloodstream Infection
Interventions
- Drug: AZD7760
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFOccurrence of Adverse Events (AEs)
measured Day 1 to Day 181
Occurrence of Medically-attended Adverse Events (MAAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)
measured Day 1 to Day 361
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed